NewsBenzingaTango Therapeutics presenterà dati aggiornati dallo studio di Fase 1/2 di vopimetostat in combinazione con daraxonrasib o zoldonrasib in pazienti con PDAC metastatico e NSCLC con MTAPdel/RASmut al Congresso ESMO 2026 Tango Therapeutics presenterà dati aggiornati dallo studio di Fase 1/2 di vopimetostat in combinazione con daraxonrasib o zoldonrasib in pazienti con PDAC metastatico e NSCLC con MTAPdel/RASmut al Congresso ESMO 2026 Benzinga 2026.10.16 11:05 (GMT+0) Open on Benzinga Other news Dow Jones Today: DJIA Flat as Oil Edges Lower; Tech Stocks Rebound - TipRanks.com Gas Never Used To Be This Pricey In October; West Coast Imports Are Surging Wells Fargo Maintains Equal-Weight on Sonoco Products, Lowers Price Target to $53 Piper Sandler Maintains Neutral on WaFd, Lowers Price Target to $31 INTC vs. AMD: Which AI Chip Stock Could Continue to Rally After Today? - TipRanks.com VinFast Says Real Estate Could Cover Its EV Cash Burn
